Results 71 to 80 of about 188,311 (274)

Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD‐ADRD): Executive summary of recommendations for primary care

open access: yesAlzheimer's &Dementia, EarlyView.
Abstract US clinical practice guidelines for the diagnostic evaluation of cognitive impairment due to Alzheimer's disease (AD) or AD and related dementias (ADRD) are decades old and aimed at specialists. This evidence‐based guideline was developed to empower all—including primary care—clinicians to implement a structured approach for evaluating a ...
Alireza Atri   +10 more
wiley   +1 more source

Efficacy, Safety, Pharmacokinetics, and Immunogenicity of ABBV‐154 in Adults With Glucocorticoid‐Dependent Polymyalgia Rheumatica: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective An unmet need exists for glucocorticoid‐sparing treatments for patients with polymyalgia rheumatica (PMR). The antibody‐drug conjugate ABBV‐154 comprises adalimumab conjugated to a glucocorticoid receptor modulator. We evaluated ABBV‐154 versus placebo in patients with glucocorticoid‐dependent PMR.
Robert F. Spiera   +14 more
wiley   +1 more source

FedGlu: A personalized federated learning-based glucose forecasting algorithm for improved performance in glycemic excursion regions [PDF]

open access: yesarXiv
Continuous glucose monitoring (CGM) devices provide real-time glucose monitoring and timely alerts for glycemic excursions, improving glycemic control among patients with diabetes. However, identifying rare events like hypoglycemia and hyperglycemia remain challenging due to their infrequency.
arxiv  

GlyTwin: Digital Twin for Glucose Control in Type 1 Diabetes Through Optimal Behavioral Modifications Using Patient-Centric Counterfactuals [PDF]

open access: yesarXiv
Frequent and long-term exposure to hyperglycemia (i.e., high blood glucose) increases the risk of chronic complications such as neuropathy, nephropathy, and cardiovascular disease. Current technologies like continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) primarily model specific aspects of glycemic control-like ...
arxiv  

Sacrificial strategy towards the formation of vascular‐like networks in volumetric tissue constructs

open access: yesBMEMat, EarlyView.
This mini‐review highlights the latest progress in the sacrificial template‐enabled creation of patent vascular‐like networks, which can be incorporated into volumetric tissue constructs. Such microchannel networks can provide an immediate supply of nutrition and O2 to those cells residing next to the channels.
Christian Buckley   +5 more
wiley   +1 more source

The effect and underlying mechanisms of titanium dioxide nanoparticles on glucose homeostasis: A literature review

open access: yesJournal of Applied Toxicology, Volume 43, Issue 1, Page 22-31, January 2023., 2023
Abstract Titanium dioxide (TiO2) is used extensively as a white pigment in the food industry, personal care, and a variety of products of everyday use. Although TiO2 has been categorized as a bioinert material, recent evidence has demonstrated different toxicity profiles of TiO2 nanoparticles (NPs) and a potential health risk to humans.
Vida Mohammadparast, Beth L. Mallard
wiley   +1 more source

Antibacterial hydrogel: The sniper of chronic wounds

open access: yesBMEMat, EarlyView.
The treatment of chronic wounds has always been an important challenge in the medical field. We focus on hydrogels not only because they provide a moist healing environment but also because compared with traditional dressings, they can effectively prevent and treat infections, reduce wound pain and scar formation.
Shengtai Bian   +6 more
wiley   +1 more source

An open‐label, single‐arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR‐positive, HER2‐negative advanced breast cancer patients: BRIGHT‐1 trial

open access: yesCancer Communications, EarlyView.
Abstract Background Bireociclib (XZP‐3287) is a novel selective cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitor, with a favorable safety profile demonstrated in preclinical and phase I studies. BRIGHT‐1 aimed to further explore the efficacy and safety of bireociclib monotherapy in patients with locally advanced, recurrent or metastatic, hormone ...
Jiayu Wang   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy